Belimumab study for adults with systemic lupus
Part of Immune system & allergy, Skin clinical trials.
This study looks at people with systemic lupus (lupus) who have already started belimumab (a lupus medicine). It mainly focuses on whether participants who meet lupus diagnosis rules and choose to join can be followed in the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor-confirmed diagnosis of systemic lupus based on accepted classification rules
- You are 18 years old or older
- You have already received at least one dose of belimumab by injection or infusion
- You agree to join the study and sign the consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
This study compares two medications, Telitacicept and Belimumab, to see which works better for people with active lupus that hasn't improved with standard treatments. The goal is to find a more effective option for managing symptoms.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
This study looks at how the drug belimumab affects the long-term course of lupus. It compares patients who receive belimumab to similar patients who do not, to see if it helps control disease activity over time.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.